Show simple item record

dc.contributor.author
Wahl, Anna-Sophia
dc.contributor.author
Correa, Daphne
dc.contributor.author
Imobersteg, Stefan
dc.contributor.author
Maurer, Michael Andreas
dc.contributor.author
Kaiser, Julia
dc.contributor.author
Augath, Marc Aurel
dc.contributor.author
Schwab, Martin E.
dc.date.accessioned
2020-11-11T14:38:13Z
dc.date.available
2020-05-21T02:31:02Z
dc.date.available
2020-05-22T13:43:20Z
dc.date.available
2020-11-11T14:38:13Z
dc.date.issued
2020-07
dc.identifier.other
10.1007/s13311-020-00864-z
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/416185
dc.identifier.doi
10.3929/ethz-b-000416185
dc.description.abstract
Antibody-based therapeutics targeting CNS antigens emerge as promising treatments in neurology. However, access to the CNS is limited by the blood–brain barrier. We examined the effects of a neurite growth-enhancing anti-Nogo A antibody therapy following 3 routes of administration—intrathecal (i.t.), intravenous (i.v.), and subcutaneous (s.c.)—after large photothrombotic strokes in adult rats. Intrathecal treatment of full-length IgG anti-Nogo A antibodies enhanced recovery of the grasping function, but intravenous or subcutaneous administration had no detectable effect in spite of large amounts of antibodies in the peripheral circulation. Thus, in contrast to intravenous and subcutaneous delivery, intrathecal administration is an effective and reliable way to target CNS antigens. Our data reveal that antibody delivery to the CNS is far from trivial. While intrathecal application is feasible and guarantees defined antibody doses in the effective range for a biological function, the identification and establishment of easier routes of administration remains an important task to facilitate antibody-based future therapies of CNS disorders.
en_US
dc.format
application/pdf
en_US
dc.language.iso
en
en_US
dc.publisher
Springer
en_US
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
CNS antibody delivery
en_US
dc.subject
Stroke
en_US
dc.subject
Intrathecal
en_US
dc.subject
Functional recovery
en_US
dc.subject
Anti-Nogo antibody therapy
en_US
dc.title
Targeting Therapeutic Antibodies to the CNS: a Comparative Study of Intrathecal, Intravenous, and Subcutaneous Anti-Nogo A Antibody Treatment after Stroke in Rats
en_US
dc.type
Journal Article
dc.rights.license
Creative Commons Attribution 4.0 International
dc.date.published
2020-05-06
ethz.journal.title
Neurotherapeutics
ethz.journal.volume
17
en_US
ethz.journal.issue
3
en_US
ethz.pages.start
1153
en_US
ethz.pages.end
1159
en_US
ethz.version.deposit
publishedVersion
en_US
ethz.grant
The Nogo-A receptor complex after CNS injury and its role in the developing and adult nervous system
en_US
ethz.identifier.wos
ethz.identifier.scopus
ethz.publication.place
New York, NY
en_US
ethz.publication.status
published
en_US
ethz.grant.agreementno
294115
ethz.grant.fundername
EC
ethz.grant.funderDoi
10.13039/501100000780
ethz.grant.program
FP7
ethz.date.deposited
2020-05-21T02:31:05Z
ethz.source
WOS
ethz.eth
yes
en_US
ethz.availability
Open access
en_US
ethz.rosetta.installDate
2020-11-11T14:38:27Z
ethz.rosetta.lastUpdated
2021-02-15T20:41:47Z
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=Targeting%20Therapeutic%20Antibodies%20to%20the%20CNS:%20a%20Comparative%20Study%20of%20Intrathecal,%20Intravenous,%20and%20Subcutaneous%20Anti-Nogo%20A%20Antibody%20Tre&rft.jtitle=Neurotherapeutics&rft.date=2020-07&rft.volume=17&rft.issue=3&rft.spage=1153&rft.epage=1159&rft.au=Wahl,%20Anna-Sophia&Correa,%20Daphne&Imobersteg,%20Stefan&Maurer,%20Michael%20Andreas&Kaiser,%20Julia&rft.genre=article&rft_id=info:doi/10.1007/s13311-020-00864-z&
 Search print copy at ETH Library

Files in this item

Thumbnail

Publication type

Show simple item record